CO-ADTRAN
30.4.2024 14:01:32 CEST | Business Wire | Press release
Adtran today announced that Commnet Broadband is leveraging Intellifi® as part of its Mosaic One software-as-a-service (SaaS) solution to enhance in-home connectivity as the service provider scales across the American Southwest. The cloud-managed Wi-Fi solution will enable Commnet Broadband to deliver a seamless, always-on mesh Wi-Fi experience, boosting subscriber satisfaction while driving new efficiencies. With a strong commitment to digital inclusion, Commnet Broadband is extending its reach into more underserved rural communities, connecting them with reliable and high-quality internet services. Deploying Mosaic One for remote service activation and troubleshooting, along with Intellifi® for AI-driven insights and complete control over the home Wi-Fi environment, enables the company to efficiently manage its expansive and diverse network infrastructure.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240430732731/en/
Adtran’s Mosaic One and Intellifi® are helping Commnet deliver robust Wi-Fi services to underserved communities. (Photo: Business Wire)
“At Commnet Broadband, our mission is to empower underserved regions of America through reliable and personalized internet access. With Adtran’s Intellifi® solution, we’re taking our service delivery capabilities to the next level, ensuring uninterrupted and hassle-free Wi-Fi for both fiber and fixed wireless customers across our footprint,” said Scott Horne, CEO of Commnet Broadband. “One key advantage of our new system is the enhanced visibility it offers into customer premises, reducing the need for tier 1 tech support and minimizing truck rolls. Features like network-wide speed tests will enable us to analyze detailed heat maps, revealing our network’s strengths and pinpointing areas for improvement. This clear understanding of latency and speed capabilities will help us uplift the most isolated communities, ensuring we make a real and impactful difference.”
Adtran’s Intellifi®, part of the Mosaic One suite, provides a robust, cloud-hosted portal that transforms home Wi-Fi management for Commnet Broadband’s subscribers. It enhances customer support with features like Intellifi® MeshView, an operator portal that facilitates automated issue detection and remote resolution. The Intellifi® mobile app supports subscriber self-installs and offers comprehensive network control, including parental settings and device management. Mosaic One equips network engineers with predictive tools that monitor network access and identify at-risk connections. This proactive approach not only helps preemptively address issues, thereby reducing the need for on-site repairs, but it also enhances network reliability and subscriber uptime. Adtran’s Wi-Fi 6 service delivery gateways (SDGs) and mesh satellites also help ensure an exceptional Wi-Fi experience for subscribers.
“We’re excited to support Commnet Broadband as they expand their reach into more digitally excluded areas and elevate their services for all subscribers. With our Mosaic One and Intellifi® solutions, they can harness the full potential of managed Wi-Fi. That means delivering true Gigabit and multigigabit speeds and a superior level of service,” commented John Scherzinger, GM of Americas sales at Adtran. “The comprehensive telemetry, insights and user experience data that Intellifi® provides will empower Commnet Broadband to tailor services more precisely to each customer’s needs. Our virtual field technician feature can also cut operational costs, generating substantial savings per truck roll. Moreover, our technology creates new revenue opportunities, enabling Commnet Broadband to offer differentiated services that cater to the specific needs of communities, businesses and families.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
About Commnet Broadband
Commnet Broadband, wholly owned subsidiary of ATN International, Inc. (NASDAQ: ATNI), provides high-quality broadband communications services to carrier customers in rural America and Tribal communities, driving digital inclusion and providing access to education, work, healthcare, safety, entertainment, and community connectivity. Learn more at www.commnetbroadband.com.
Published by
ADTRAN Holdings, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240430732731/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom